{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-205557","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.544793+00:00","generated_at":"2026-06-12T02:04:36.060625+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Seres reports Q2 2023 net income of $46.6M on $125M VOWST milestone; early launch demand strong","bullets":["Net income $46.6M vs net loss $64.7M YoY; $125M milestone from Nestlé upon FDA approval of VOWST.","VOWST net sales $1.6M in first partial quarter; 610 prescription forms, 282 patient starts from 480+ HCPs.","Cash $229.5M; new $250M Oaktree debt facility, drew $110M at close, $53.4M to retire prior debt.","SER-155 Phase 1b Cohort 1: favorable tolerability, reduced ESKAPE pathogen domination; Cohort 2 data mid-2024.","R&D expense $46.8M, G&A $28.1M; VOWST commercial mfg costs to capitalize post-approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-205557","json":"https://secwatch.observer/filing/0001193125-23-205557.json","markdown":"https://secwatch.observer/filing/0001193125-23-205557.md","text":"https://secwatch.observer/filing/0001193125-23-205557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523205557/0001193125-23-205557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523205557/d541674d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:04:36.060625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ac5aa00ecaa2dc50882a0f87a3ffc44c4542343","claim":"Seres Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Seres Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter ended June 30, 2023 and provided operational updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523205557/0001193125-23-205557-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}